Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment.
10.3760/cma.j.cn501113-20210119-00032
- VernacularTitle:直接抗病毒药物治疗后丙型肝炎相关肝细胞癌的发生与复发
- Author:
Yu Qing YANG
1
;
Xiao Yuan XU
1
Author Information
1. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Review
- Keywords:
Direct antiviral treatment;
Hepatitis C;
Hepatocellular carcinoma
- MeSH:
Antiviral Agents/therapeutic use*;
Carcinoma, Hepatocellular/drug therapy*;
Hepatitis C/drug therapy*;
Hepatitis C, Chronic/drug therapy*;
Humans;
Liver Neoplasms/etiology*;
Sustained Virologic Response
- From:
Chinese Journal of Hepatology
2022;30(1):103-106
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis C virus (HCV) RNA can be cleared from the blood circulation by direct antiviral treatment to achieve sustained virologic response (SVR). Studies have shown that SVR after direct antiviral therapy can reduce the incidence of hepatocellular carcinoma; however, monitoring for hepatocellular carcinoma is still needed. This review briefly summarizes and discusses the existing studies on the possible causes of hepatitis C secondary to HCC after antiviral therapy, which is mainly divided into epigenetic alterations and abnormal DNA methylation, HCV-related cirrhosis and abnormal DNA amplification, HBV reactivation, several aspects of occult HCV infection, and the effect of direct antiviral treatment on hepatocellular carcinoma recurrence. In few cases, direct antiviral treatment cannot completely prevent the occurrence and recurrence of hepatitis C-related hepatocellular carcinoma. Therefore, its mechanism needs to be studied and explored, and clinicians should also approach it with caution.
